These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38698526)

  • 1. Nirmatrelvir/ritonavir treatment of patients with COVID-19 taking tacrolimus: case series describing the results of drug-drug interactions.
    Shen D; Gong Y; Qian Y; Zhu J; Gao J
    J Int Med Res; 2024 May; 52(5):3000605241247705. PubMed ID: 38698526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management and Outcome of COVID-19 Infection Using Nirmatrelvir/Ritonavir in Kidney Transplant Patients.
    Giguère P; Deschenes MJ; Van Loon M; Hoar S; Fairhead T; Pazhekattu R; Knoll G; Karpinski J; Parikh N; McDougall J; McGuinty M; Hiremath S
    Clin J Am Soc Nephrol; 2023 Jul; 18(7):913-919. PubMed ID: 37099447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nirmatrelvir/ritonavir-induced elevation of blood tacrolimus levels in a patient in the maintenance phase post liver transplantation.
    Shiohira H; Arakaki S; Uehara W; Uehara H; Yamamoto K; Nakamura K
    J Infect Chemother; 2024 Jan; 30(1):77-80. PubMed ID: 37689137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19.
    Tomida T; Itohara K; Yamamoto K; Kimura T; Fujita K; Uda A; Kitahiro Y; Yokoyama N; Hyodo Y; Omura T; Yano I
    Drug Metab Pharmacokinet; 2023 Dec; 53():100529. PubMed ID: 37924724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
    Sindelar M; McCabe D; Carroll E
    J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.
    Young C; Papiro T; Greenberg JH
    Pediatr Nephrol; 2023 Apr; 38(4):1387-1388. PubMed ID: 35982345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
    Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
    Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis.
    Tsuzawa A; Katada Y; Umemura K; Sugimoto M; Nishikawa A; Sato YK; Yoshida Y; Kitada N; Yonezawa A; Nakajima D; Date H; Terada T
    J Pharm Health Care Sci; 2023 Apr; 9(1):12. PubMed ID: 37004119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interaction of Nirmatrelvir/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS.
    Qin F; Wang H; Li M; Zhuo S; Liu W
    Expert Opin Drug Saf; 2023; 22(12):1321-1327. PubMed ID: 37477905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case Report of Drug Interactions Between Nirmatrelvir/Ritonavir and Tacrolimus in a Patient With Systemic Lupus Erythematosus.
    Yamamoto N; Tsuchiya Y; Fukuda M; Niiro H; Hirota T
    Cureus; 2024 Jan; 16(1):e52506. PubMed ID: 38371142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
    Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
    Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report.
    Akamatsu H; Kohno Y; Hashizume J; Nakagawa H; Kodama Y; Kawano H; Maemura K; Ohyama K
    J Infect Chemother; 2024 Sep; 30(9):928-933. PubMed ID: 38360184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.